Multiple Sclerosis & Demyelinating Autoimmune/Neurological Disorders
Due to the clinical and pathological similarities of experimental autoimmune encephalomyelitis (EAE) and MS, EAE has been used as a model for the study of human demyelinating disease. Both EAE and MS are characterized by a relapsing-remitting disease course with subsequent progressive disability. EAE is characterized by chronic inflammatory demyelination of the central nervous system (CNS) and involves autoimmune CD4+ Th1 cells. These cells develop in the peripheral lymphoid organ and travel to the CNS causing an immune response. The development of T cells is controlled largely by the expression of various cytokines, as well as cellular adhesion molecules.
Pathology of MS
The pathology of MS starts with the activation and proliferation of T cells in the peripheral lymphoid organs. MMPs and adhesion molecules assist the T cells in crossing the blood brain barrier where the T cell engages antigen-MHC complexes in the CNS causing nerve cell damage.
MD Biosciences is an experienced research partner with strength in designing pharmacology efficacy studies for Multiple Sclerosis (MS) demyelination disorders. That's why we offer models to study MS and demyelination. Don't see a readout or model listed below that you need? Our scientists are experienced in validating models quickly from the literature. Contact a scientist to discuss your model requirements.
For interest in EAE Clinical Batch Release Testing Services, please contact us at firstname.lastname@example.org with the subject title "EAE Batch Release Testing."